Orencia approved for polyarticular juvenile idiopathic arthritis

Orencia (abatacept) is now licensed for use in children aged 6 years and older in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) where there has been an insufficient response to other DMARDs including methotrexate.

The safety and efficacy of Orencia have not been evaluated in children under 6 years of age and, therefore, it is not licensed in this age range.

View Orencia drug record

Further information: BMS

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases